Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Drug Development and Industrial Pharmacy|April 17, 2019
The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicinMohammad A M Momin, Ian G Tucker, Shyamal C Das
International Journal of Pharmaceutics|September 5, 2018
High dose dry powder inhalers to overcome the challenges of tuberculosis treatmentMohammad A M Momin, Ian G Tucker, Shyamal C Das
Drug Development and Industrial Pharmacy|May 20, 2025
Storage and in-use stability of an excipient enhanced growth (EEG) synthetic lung surfactant powder formulationMohammad A M Momin, Connor Howe, Worth Longest, et al.
Journal of Pharmaceutical and Biomedical Analysis|December 27, 2016
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosisMohammad A M Momin, Sim J Thien, Woravimol Krittaphol, et al.
Drug Development and Industrial Pharmacy|April 25, 2019
Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosisMohammad A M Momin, Shubhra Sinha, Ian G Tucker, et al.
AAPS Pharmscitech|April 16, 2021
Development and Characterization of Excipient Enhanced Growth (EEG) Surfactant Powder Formulations for Treating Neonatal Respiratory Distress SyndromeSusan Boc, Mohammad A M Momin, Dale R Farkas, et al.
Pharmaceutical Research|October 17, 2022
Development of a High-Dose Infant Air-Jet Dry Powder Inhaler (DPI) with Passive Cyclic Loading of the FormulationConnor Howe, Mohammad A M Momin, Ghali Aladwani, et al.
AAPS Pharmscitech|April 16, 2021
Performance of Low Air Volume Dry Powder Inhalers (LV-DPI) when Aerosolizing Excipient Enhanced Growth (EEG) Surfactant Powder FormulationsSusan Boc, Mohammad A M Momin, Dale R Farkas, et al.
International Journal of Pharmaceutics|July 5, 2023
Advancement of a high-dose infant air-jet dry powder inhaler (DPI) with passive cyclic loading: Performance tuning for different formulationsConnor Howe, Mohammad A M Momin, Ghali Aladwani, et al.
Pharmaceutics|August 28, 2021
Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on AerosolizationMohammad A M Momin, Bishal Raj Adhikari, Shubhra Sinha, et al.
Pageof 3